Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05478538 · ClinicalTrials.gov registry record
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
A clinical trial of NSCLC (Non-small Cell Lung Cancer) and Metastatic NSCLC - Non-Small Cell Lung Cancer, sponsored by Elephas.
- Recruiting
- Registry status
- 200
- Enrollment target
- 7
- Study locations
NCT05478538 is a study of NSCLC (Non-small Cell Lung Cancer) and Metastatic NSCLC - Non-Small Cell Lung Cancer that is actively recruiting participants, run by Elephas. The registered enrollment target is 200 participants, below the 332-participant average among 10 other NSCLC (Non-small Cell Lung Cancer) trials with a reported enrollment target (40% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT05478538, a study of NSCLC (Non-small Cell Lung Cancer) and Metastatic NSCLC - Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Elephas.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.
Conditions Studied
Interventions
- PROCEDURE Core Needle, Forceps, or Punch Biopsy
Study Locations (7)
Texas
- JPS Health Network - Fort Worth
- Baylor Scott & White Research Institute - Temple
California
- UCLA Medical Center - Los Angeles
Maryland
- James M Stockman Cancer Institute - Frederick
New York
- New York Cancer & Blood Specialists - Shirley
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Ohio
- Gabrail Cancer Center - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05478538
The ClinicalTrials.gov registry entry for NCT05478538 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 332-participant average among 10 other NSCLC (Non-small Cell Lung Cancer) trials with a reported enrollment target (40% lower). The listed sponsor is Elephas, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with NSCLC (Non-small Cell Lung Cancer) appearing as the primary indexed condition, and to 1 intervention - of which Core Needle, Forceps, or Punch Biopsy is the first listed.
NCT05478538 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Texas, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT05478538 about?
NCT05478538 is a clinical study titled "Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform". The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.
What is the current status of trial NCT05478538?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2023-01-31. Estimated completion is 2026-12.
What conditions does trial NCT05478538 study?
This clinical trial studies the following conditions: NSCLC (Non-small Cell Lung Cancer), Metastatic NSCLC - Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05478538?
The interventions under investigation include: Core Needle, Forceps, or Punch Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT05478538?
This trial is sponsored by Elephas, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05478538 being conducted?
This trial has 7 study locations across California, Maryland, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSCLC (Non-small Cell Lung Cancer)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RECRUITING · Phase 1
-
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
RECRUITING · Phase 1
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RECRUITING · Phase 1
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
Explore more on PlainTrial
NSCLC (Non-small Cell Lung Cancer)
All registered trials for this condition
Metastatic NSCLC - Non-Small Cell Lung Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.